JP2017132747A - Age production inhibitor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide AGE production inhibitors and applications thereof that are associated with particularly the care of vascular dementia prevention associated with among harmful effects caused by produced and accumulated AGEs due to in vivo glycation reaction, such as collagen and elastin.SOLUTION: According to the present invention, in the composition which contains a particular AGE production inhibitor as an active ingredient, is applicable in an external or an oral form, and contains collagen and/or collagen peptides as main components and consists of collagen and/or collagen peptides and additionally at least one selected from elastin, hyaluronic acid, and chondroitin sulfate, the effect of vascular dementia prevention is achieved by applying an optimal preparation designed by adding a particular AGE production inhibitor.SELECTED DRAWING: None

Description

The present invention relates to an AGE production inhibitor that focuses on glycation reaction of in vivo proteins.
More specifically, it is an invention related to the prevention of dementia that is difficult to improve, not only for its use as anti-aging, and its application form as an anti-glycation agent is not only systemic care including food and drink forms, It constitutes a local one and its method.

  While we have a permanent desire for mankind to “keep on being youthful forever”, what is called “anti-aging medicine”, so-called anti-aging, was born, and the medical system for overcoming the aging process and its causes has developed. It was.

Recently, a saccharification reaction has attracted attention as a risk factor for aging. The saccharification reaction means that sugar and protein (amino acids) chemically react non-enzymatically, and the generic name of substances generated by the chemical reaction is generally called AGEs (Advanced Glication End Products) It is.

  Even in healthy individuals, protein glycation occurs. The glycation is accelerated by ultraviolet rays or aging, and a final saccharification reaction product (hereinafter simply referred to as “AGEs”) is produced and accumulated. It is a risk factor that cannot be overlooked by diseases associated with recent lifestyle changes and dietary habits. For example, people with diabetes are particularly at high risk and AGEs are likely to accumulate, which accelerates various aging phenomena.

AGEs are accompanied by sclerosis and denaturation of proteins, and their progress brings about a decrease in the function of living tissues, and there are concerns about various effects on health.
Moreover, since proteins are present in body tissues such as the brain, organs, skin, scalp, scalp, nails, blood, etc., naturally, the effects of AGEs production / accumulation are systemic.

Collagen, which is a kind of protein, occupies about 30% of body weight, 40% of which is in the skin (including eyelid skin) and 10-20% is in bone and cartilage. In addition, collagen is also present in blood vessels, scalp, and organs, and saccharification occurs at each of these sites.

  Elastin, which is one of the important proteins in the body like collagen, is a fiber component that brings elasticity to keep collagen in a mesh form, and plays a role in giving elasticity to the skin.

Therefore, both collagen and elastin are directly affected by AGE production. The effects of this AGE production are specifically as follows in the skin, blood vessels and scalp.

That is, in the skin (including eyelid skin, which may be used synonymously hereinafter), glycation of proteins such as collagen protein and elastin fiber occurs, causing a biological reaction that destroys the structure of the collagen fibers that hold the skin firm. Is done. An enzyme that prevents collagen synthesis (collagenase) is also activated. As a result, the skin loses its normal elasticity, changes its color to a state free of firmness and gloss, and waste products accumulate in the skin cells. As a result, the cause of so-called yellowing and darkening is caused, and the transparency of the skin is lost.
In addition, it is often caused by lack of nutritional balance that causes rough skin during dieting. Decrease in elasticity is accelerated by the effect of saccharification.
At the heel part, so-called eye lashes stand out, and the eyelashes lose their elasticity and elasticity.

AGEs in blood have high affinity and adhesion to blood vessel cells and are likely to accumulate in the blood vessel wall. When AGEs adhere to the blood vessel wall, active oxygen is generated, and as a result of oxidizing NO (nitrogen monoxide), blood flow deteriorates. In relation to diseases such as ED, it becomes difficult to carry blood necessary for erection. It is also a phenomenon that occurs particularly when suffering from diabetes. The human penis is anatomically composed of three cylindrical parts, most of which are composed of collagen and elastin. In the erectile tissue of the cavernous body of the penis, collagen fibers and elastin fibers are one of the important components other than blood vessels and blood, and the production of AGEs has an adverse effect on the erectile tissue. Therefore, to maintain and restore male sexual function, it is extremely important to prevent the influence of AGEs on the blood vessels and the erectile tissue of the corpus cavernosum.
One problem that has become more serious in recent years is infertility treatment. Infertility treatment has different factors for men and women, so efforts for treatment are being made individually, but in the case of men, ED is often a factor, and in that respect the point of anti-glycation is Very meaningful.
On the other hand, saccharification is a direct factor for women. That is, saccharification degrades the ovum, and ovulation becomes impossible when the degree of deterioration becomes significant. In any case, anti-glycation is a common key for male and female infertility treatment.

The scalp has a dermis layer as well as the skin. When AGEs cross-linkage occurs in the dermis layer of the scalp, or when AGEs accumulate due to glycation of the main component of hair, keratin (one of proteins), hair loss, cut hair, and gray hair increase.
In addition, the elasticity of the scalp is generated by elastin, hyaluronic acid, chondroitin sulfate, etc. present in the dermis layer.

The effect on hair is also great, and as the glycation of collagen and elastin present in the dermis layer progresses, the dermis layer hardens, causing adverse effects on secretory glands, hair follicles, blood vessels and the like. As a result, the vitality of making hair declines, and the hair quality is further affected by the loss of elasticity and gloss. The hair papilla located at the root of the hair roots controls the hair growth, but the hair matrix cells divide and keratinize into hair after receiving a stimulus from the hair papilla, and extend from the scalp. Here, when AGEs accumulate in the hair root, the functions of the hair papilla and hair matrix cells are limited. As a result, hair cannot grow sufficiently and hair loss occurs. Eyelashes can be regarded as body hair that grows at the ends of the eyelids, but as with hair, protein degradation such as collagen and elastin occurs due to the effect of glycation on the eyelid skin, and the elasticity and elasticity of the eyelashes disappear, The regeneration cycle is also reduced.

In addition, there are melanocytes adjacent to the hair matrix cells, and when the hair matrix cells divide, they take in melanin pigment from the melanocytes and become black or brown hair. However, when AGEs accumulate in melanocytes, they can supply melanin sufficiently. It disappears and causes gray hair.

  Thus, anti-glycation (countermeasures against glycation), that is, measures against AGEs production, are attracting a great deal of attention from the viewpoint of not only skin and blood vessel care but also scalp, hair and eyelash care.

  As for collagen, when it is young, collagen synthase is actively secreted, so abundant collagen is produced and the normal condition of skin quality, blood vessels, and scalp is maintained, but collagen synthase decreases with age. AGE production proceeds. If such a stage further progresses, local care such as so-called UV countermeasures and moisturizing countermeasures is no longer sufficient, and systemic care including eating and drinking becomes essential. The same applies to elastin.

  As a result of diligent research in view of various problems as described above, the present applicant has found that the problem can be solved by optimally applying a specific AGE production inhibitor in an external or oral form. (Patent Document 1).

Furthermore, in the course of examining the knowledge and the like according to the present invention, the present applicant has found that a specific AGE production inhibitor is also effective for the prevention of vascular dementia, and has completed the present invention.

Dementia is a disorder in the brain and causes symptoms such as memory impairment, disorientation, impaired computing ability, aphasia, and agnosia due to functional decline. General classification of dementia by causative disease includes vascular dementia, degenerative dementia, diffuse (Parkinson's disease-like) dementia, frontotemporal dementia, and the like. Various treatments have been tried, but no effective therapeutic agent has been found yet.

On the other hand, in the case of mild cognitive impairment before dementia (a state in which cognitive function is reduced but not dementia), it is said to have a high preventive effect, and development of a preventive agent is expected. In an attempt to prevent aging, research and development of AGEs production inhibitors have been carried out (for example, Patent Documents 2 to 6), but no invention has been specified for the prevention of dementia. Thus, there is no application example of the AGEs production inhibitor which paid its attention to prevention of vascular dementia.

Vascular dementia tends to develop when blood vessel aging is the cause. As described above, since aging is accelerated when AGEs adhere to the blood vessel wall, it can be said that suppressing its production is an effective means for prevention.

Japanese Patent Application No. 2015-213529 JP 2012-77042 A JP 2013-184974 A Japanese Patent Laying-Open No. 2015-96498 JP 2015-224201 A JP 2015-224202 A

  In view of the above problems, the object of the present invention is to prevent dementia, which is particularly difficult to improve by treatment among adverse effects caused by AGEs produced and accumulated as a result of in vivo saccharification reactions such as collagen and elastin. It is in providing the AGEs production inhibitor which concerns.

  As a result of diligent studies to solve the above problems, the present inventor aims to prevent glycation of these proteins in vivo while supplementing essential collagen, elastin, hyaluronic acid and chondroitin sulfate in tissues in vivo. Providing a composition in combination with an AGEs production inhibitor, or providing its optimal method of use to prevent decline in collagen function, etc., and to exhibit a function useful for preventing mild cognitive impairment The headline and the present invention were completed.

  An important factor in developing a prophylactic agent for vascular dementia is the effect of aging. Here, it is necessary to consider from two aspects in order to prevent deterioration of in vivo functions of collagen and elastin due to aging. Quantitative supplementation from the outside and internal care in in vivo tissues.

In the former, it is necessary to supplement essential components in the body. Especially, it is important to supplement collagen and elastin which are related to tissue elasticity, and hyaluronic acid and chondroitin sulfate, which can sufficiently exert moisture retention. It is. In the present invention, collagen or collagen peptide is an essential component, and elastin, hyaluronic acid and chondroitin sulfate are combined as a supplement component.

The latter is to suppress the production of AGEs in order to prevent the decrease of collagen and elastin after the proteins present in the living body, particularly the influence of saccharification reaction. Here, as an AGEs production inhibitor, in view of the use of mild dementia prevention, a material having an AGEs production inhibitory effect among various materials having blood flow and nourishing tonic effects is found as suitable after screening. It was decided to use for this invention. That is, one or more selected from choline compounds such as yamabushitake extract, ginkgo biloba extract, acetylcholine, choline, glycerophosphocholine, and phosphatidylcholine have been used as active ingredients. These are all novel AGEs production inhibitors.

That is, according to this invention, the AGEs production inhibitor as described in the following (1) thru | or (3) and its use are provided.

(1) An AGEs production inhibitor comprising as an active ingredient at least one selected from Yamabushitake water extract, Ginkgo biloba extract, acetylcholine, choline, glycerophosphocholine and phosphatidylcholine.
(2) The AGEs according to claim 1, wherein a composition comprising at least one selected from elastin, hyaluronic acid and chondroitin sulfate is added to collagen and / or collagen peptide as a main component. Production inhibitor.
(3) The AGE production inhibitor according to claim 2, wherein the collagen peptide is an oligopeptide.

  According to the present invention, by applying a specific AGEs production inhibitor optimally in an oral form, a decrease in the amount of collagen and elastin in blood vessels can be prevented, and functional improvement and normalization can be achieved. As a result, vascular dementia can be prevented.

  Hereinafter, specific modes for carrying out the present invention will be described in detail. However, the technical scope of the present invention is not limited to the specific modes disclosed below.

  The first invention in the present invention is a specific AGEs production inhibitor that was found not only for preventing skin aging due to aging and for improving rough skin during dieting, but also for preventing vascular dementia. That is, in view of the use of mild vascular dementia, various materials that can suppress AGE production were screened. As a result, choline compounds such as Yamabushitake water extract, Ginkgo biloba extract, acetylcholine, choline, glycerophosphocholine, and phosphatidylcholine are preferable. It was found as a new material.

  In the present invention, in order to enhance the AGEs production inhibitory effect to one or more selected from these specific AGEs production inhibitors, Yamabushitake water extract, Ginkgo biloba water extract, acetylcholine, choline, glycerophosphocholine, phosphatidylcholine, etc. One or more selected from the choline compounds can be used.

Yamabushitake (Yamabushitake) is a coral spider mushroom that grows on the trunks and stumps of broad-leaved trees such as kunugi, walnuts, shii or mizunara, and is widely distributed in Japan, China, Europe, North America and North Africa. It is called Hericium erinaceum.

As the Yamabushitake extract of the present invention, it is preferable to use an extract obtained by extracting fruit bodies from powder or the like, or using mycelium material itself with an aqueous solvent. As the aqueous solvent, water and / or an extract extracted with a lower alcohol can be used, and ethanol is preferable as the lower alcohol. Particularly preferred is a water extract.

As the ginkgo extract, it is preferable to use an extract obtained by drying leaves of Ginkgo (scientific name: Ginkgo biloba) and extracting with an aqueous solvent. As the aqueous solvent, water and / or an extract extracted with a lower alcohol can be used, and ethanol is preferable as the lower alcohol. Particularly preferred is a water extract.

In the present invention, a composition to which the above specific AGEs production inhibitor (one or more selected from choline compounds such as yamabushitake extract, ginkgo biloba extract, acetylcholine, choline, glycerophosphocholine and phosphatidylcholine) is added as it is. Although it can be used, it can also be used as an active ingredient (functional ingredient) for applying as an external preparation or a form of food and drink.

When applied externally, the combination use of a known percutaneous absorption enhancer is optional, and the formulation is designed according to the site of use. These applications can suppress adhesion and accumulation of AGEs to the blood vessel wall by the absorbed AGEs production inhibitor, thereby suppressing oxidation of nitric oxide by active oxygen and improving blood flow. Of course, the effect is the same in oral application such as food and drink, but further expectation can be expected when oral such as food and drink is used in combination with external use.

The external preparation of the present invention includes forms acceptable as pharmaceuticals, quasi drugs, and cosmetics, and the dosage form is not particularly limited as long as it does not impair the object of the present invention. Examples thereof include known forms such as creams, ointments, emulsions, liniments, pastes, lotions, emulsions, essences, gels and tonics.

  As the formulation base (excipient) at the time of formulation design, any liquid and solid raw materials acceptable for skin application can be used widely. At that time, various general-purpose additives such as a humectant, a preservative, and an antioxidant can be added as necessary.

Examples of humectants include urea, glycerin, propylene glycol, 1,3-butylene glycol, sorbitol, mannitol, polyethylene glycol, dipropylene glycol and other polyhydric alcohols, ceramides, heparin-like substances, glucosamine, fucoidan, Examples include trimethylglycine, betaine, seaweed extract (Arge colloid) and the like. The combined use of the moisturizing agent is a useful choice as a prescription design particularly when intended to improve rough skin that may occur during dieting.

  Examples of the preservative include benzoate, sorbate, dehydroacetate, p-hydroxybenzoate, benzalkonium chloride, hinokitiol, resorcin, ethanol, phenoxyethanol, and the like.

  Examples of the antioxidant include dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate, ascorbic acid and the like.

  In addition to the active ingredient of the present invention, other functional ingredients usually used in external preparations can be arbitrarily blended within a range not impairing the effects and purposes of the present invention. Specifically, for example, lysozyme chloride, glycyrrhizic acid or salts thereof, anti-inflammatory agents such as allantoin, immunostimulants such as beta glucan, glucosyl hesperidin, citrulline, vitamin E nicotinate, nicotinic acid, nicotinic acid amide, benzyl nicotinate, Peripheral vasodilators such as ginger tincture, assembly extract, red pepper tincture, antibacterial agents such as hinokitiol, benzalkonium chloride, undecylenic acid, placenta extract, liver extract, oyster extract, altea extract, onionis extract, Kawaramugi extract, red ginseng extract, red ginseng extract, deer ganoderma extract, persimmon (banana peel) extract, ginger pepper extract, Japanese persimmon root extract, Sasayuri extract, western yarrow extract, western southern anther (dried seeds) ) Extract, sage extract, celery extraction , Soybean Extract, Tachikaku Extract, Chinpipe Extract, Hikikokoshi Extract, Fuquidan Popo Extract, Button Extract, Macombu Extract, Melissa Extract, Yuzu Extract, Resveratrol, Lactobacillus Culture Extract, etc. -Various extracts derived from microorganisms and extracts obtained by fermenting vegetables, fruits and wild grasses (hereinafter referred to as wild grass fermented extracts). Examples of the raw material for fermenting wild grass include, for example, mugwort, dokudami, kitachialoe, turmeric, ginseng, wolfberry, pigeon, hypericum, umbilical cabbage, litchi, dandelion root, ginseng leaf, peach leaf, ginkgo biloba leaf, Seeds, Ninja, Fig leaf, Hubgrass, Safflower, Ezokogi, Achacharu, Lacanka, Eucommia leaf, Enmay grass, Loquat leaf, Morohaya, wolfberry leaf, Settsutsuboku, Akamegashiwa, Psyllium, Tulsi, Daylily, Pine leaf, Nanten leaf, Japanese cedar, Amadokoroko, Tsuyukusa, Megusuri tree, Tsuruna, Yam, Oyster leaf, Chamomile, Karin, Perilla leaf, Tangerine peel, Ginger, Mulberry leaf, Senshinren, Kumquat, Onion husk, Seven ginseng, Kyodo root, Jujube , Salacia, pepper, yew, red ginseng, Louis , Amla berries, boxweed, boxed bean, muirabuama, ibonashi tsuji rakuji, cat's claw, kombu, funori, mandarin, apple, pineapple, grape, fig, ume, melon, grapefruit, lemon, apricot, carrot, onion, parsley, burdock , Garlic, rakkyo, cabbage, shiitake and the like can be appropriately selected and used according to the application.

  Other AGEs production inhibitors include, for example, flax, amadokoroko, olives, kanaoi, lindens, spirea, yellowflowers, roses, sunflowers, purple, yellowtails, bituminous, ashwagandha, licorice, ginseng, black corn, Examples include plant extracts such as Tribulus, Tonkat Ali, Garlic, Pueraria, Maca, Muirapuama, Moringa, Meshimakobu, and Royal Jelly.

As oral forms, food and drink, etc., for example, it can be formulated into known forms such as capsules, tablets, granules, powders, syrups, liquids and the like and used freely. Specific examples of foods and drinks include, for example, nutritional supplements such as drinks and supplements, foods for specified health use, functional foods, health foods, and various general processing of soft drinks, soups, cookies, candy, gummies, gums, etc. Food. As the excipient at that time, any liquid and solid raw materials that are acceptable for internal use can be widely used. However, in consideration of the effect of anti-glycation, caution is required in selecting a sweetener. That is, those that are difficult to saccharify should be selected. For example, sugar alcohols such as sorbitol, maltitol, erythritol, lactitol, xylitol, trehalose and stevia, rahan fruit extract, aspartame of synthetic sweetener, and the like are preferably used.

  As oral supplements such as food and drink, a known nutritional tonic or blood circulation promoter may be used in combination as long as the effects of the present invention are not impaired.

For example, as a nourishing tonic, there can be exemplified a suppon extract, a beetle extract, a cinnamon tincture, a loachfish extract, an Ezocogi extract, a Tochu extract, a kashu extract and the like.

Examples of the blood circulation promoter include glucosyl hesperidin, citrulline, vitamin E nicotinate, nicotinic acid, nicotinic acid amide, benzyl nicotinate, ginger tincture, chili pepper tincture, and rosemary acid.

The second invention is an invention that can be made in the process of pursuing the first invention described above, and provides an optimal composition for preventing vascular dementia.

That is, according to the present invention, a specific AGEs production inhibitor is added to a composition comprising at least one selected from elastin, hyaluronic acid and chondroitin sulfate based on collagen and / or collagen peptide. An AGEs production inhibitor for the prevention of vascular dementia is provided.

Here, the specific AGEs production inhibitor added for the prevention of dementia is one kind selected from choline compounds such as the aforementioned Yamabushitake extract, Ginkgo biloba extract, acetylcholine, choline, glycerophosphocholine and phosphatidylcholine. That's it.

  Collagen is not particularly restricted, but considering absorbability, collagen peptides, particularly oligopeptides composed of “proline-hydroxyproline” and / or “hydroxyproline-glycine” (less than 10 peptides) and atelocollagens preferable.

  Elastin is an elastic fiber having a role to support collagen fibers isolated from mammals such as pigs and cattle and fish such as tuna and salmon. In consideration of absorbability in the body, it is preferable to use those having an average molecular weight of around 100,000, which are enzymatically hydrolyzed by proteolytic enzymes such as elastase, pepsin and pronase, or hydrolyzed by acid. Furthermore, those having an average molecular weight of about 20,000 are preferable because of easy solubilization.

  Hyaluronic acid is a high-molecular polysaccharide in which N-acetylglucosamine and glucuronic acid are bonded to each other in beta 1,4, and preferably has a low molecular weight obtained by degrading hyaluronic acid with an enzyme such as hyaluronidase (average molecular weight around 100,000). Can be used.

  Chondroitin sulfate is a simple substance such as chondroitin 6-sulfate and chondroitin 4-sulfate, or a mixture thereof. The molecular weight is not particularly limited, but an average molecular weight of 50,000 is preferable in view of absorbability in the body. In the present invention, a chondroitin sulfate salt can also be used, and the type of the salt is not particularly limited, but a sodium salt or potassium salt is preferred.

  The significance of combining collagen and elastin with an AGEs production inhibitor is the dual effect of maintaining the original functionality of the protein in the body while supplementing the absolute amount while suppressing glycation of the protein present in the body with the AGEs production inhibitor. Is what you expect. As a result, the maintenance of homeostasis (homeostasis) is achieved.

The application of the active ingredient in the second invention, that is, the specific AGEs production inhibitor is the same as in the first invention. The parenteral or oral form is the same as that of the first invention, and collagen, elastin, hyaluronic acid and chondroitin sulfate can be arbitrarily mixed depending on the application site and the form of preparation. 0.01 to 20% by weight, preferably 0.3 to 10% by weight is sufficient.
The AGEs production inhibitor is preferably in the range of 1: 0.01 to 1:20, preferably 1: 0.1 to 1:10, based on the blended amount.

  The AGEs production inhibitor or composition thereof obtained in the first and second inventions is performed daily, preferably between meals, when taken in an oral form such as food and drink, and at least once a day when used externally. Appropriate amount should be applied to the affected area. Ideally, take it daily orally and continue internal care, and take external care when using. That is, it is preferable in terms of effect that oral care is the main and external care is the secondary.

  As described above, according to the present invention, AGEs production suppression that can solve the problems of in vivo saccharification reaction, in particular, the absolute amount of in vivo proteins such as collagen and elastin lost due to aging and functional decline. An agent or a composition thereof and a method for using these agents are also provided, thereby effectively preventing vascular dementia.

Hereinafter, the present invention will be described more specifically by way of examples (manufacturing examples and test examples and formulation examples of effects), but the scope of the present invention is not limited to these examples.
<Production Example 1> Yamabushitake extract 5 kg of water was added to 100 g of dried fruit body of Yamabushitake, followed by extraction at 50 ° C. for 6 hours and filtration to obtain a Yamabushitake extract.
<Production example 2> Ginkgo biloba extract 5 kg of water was added to 500 g of dried ginkgo biloba leaves, heated and extracted at 40 ° C for 12 hours, and filtered to obtain a ginkgo biloba water extract.

<Test Example 1> AGEs production inhibitor test (test method)
The entire test was performed according to the method of Yokozawa et al. (Yokozawa, T .; Nakagawa, T .; Journal of Traditional Medicines. 18, 107-112 (2001)).
(1) Preparation of reaction solution D-glucose, D-(-)-fructose and BSA (bovine serum albumin) were added to 100 mM phosphate buffer (pH 7.4) and dissolved, and 25 mM, 25 mM, 10 mg / kg, respectively. The reaction solution was prepared to be mL.
(2) Sample preparation Samples (each extract of Production Examples 1 and 2 and the choline compound of the present invention) and purified water as a control were subjected to the test. In addition, aminoguanidine was used as a comparative control (positive control) and prepared with purified water to a final concentration of 0.2 mM.
(3) Test procedure The sample and control prepared to each concentration were added to each test tube, a phosphate buffer solution was added to the control, and a reaction solution was added to other than the control, followed by airtight mixing. These test solutions were incubated at 60 ° C. for 18 hours. After the incubation, the test tube was cooled on ice and returned to room temperature, and the fluorescence intensity was measured with a spectrofluorometer (wavelength; excitation 360 nm, fluorescence 450 nm). The AGEs production inhibition rate was determined by the following equation.

AGE production inhibition rate (%) =
[1- (Sample fluorescence intensity−Sample blank fluorescence intensity / Control fluorescence intensity
-Fluorescence intensity of control blank)] × 100

(Results and discussion)
The results are shown in Tables 1 and 2. As is clear from this result, it is clear that the functional materials of the present invention all have a high AGEs production inhibitory effect, and by applying these optimally in an external and / or oral form, vascular tissue Decrease in the amount of collagen and elastin can be prevented, and the functional improvement and normalization of the present invention can be achieved.

Although the formulation example of this invention is given to the following, the scope of the present invention is not limited to the following formulation example.

Table 3 shows examples of drink formulations. All of these five formulations had the intended effect of the present invention.

Table 4 shows formulation examples of lotions. All of these five formulations had the intended effect of the present invention.

Claims (3)

An AGEs production inhibitor comprising as an active ingredient at least one selected from Yamabushitake water extract, Ginkgo biloba extract, acetylcholine, choline, glycerophosphocholine and phosphatidylcholine. The AGE production inhibitor according to claim 1, wherein a composition comprising at least one selected from elastin, hyaluronic acid and chondroitin sulfate is added to collagen and / or collagen peptide as a main component. . The AGE production inhibitor according to claim 2, wherein the collagen peptide is an oligopeptide.